

**In the Claims:**

1. (currently amended) A multilayered, film-shaped administration form for transmucosal administration of at least one active substance, said administration form being applied to the oral mucosa of a herbivore, to the human oral mucosa, to the human nasal mucosa or to the human vaginal mucosa in a manner avoiding mucosal irritation, said administration form comprising:

a base mass for producing said administration form, said base mass comprising at least one matrix-forming polymer and at least one pharmaceutical active substance which is present in salt form, wherein said at least one matrix-forming polymer is selected from the group consisting of pullulan, polyacrylamides, chitosan, arabinogalactan, galactomannan, agar-agar, agarose and carrageenan, said base mass having a pH value in the presence of water or of a water-containing solvent mixture, wherein said administration form is a dried film, and wherein, during the production of said administration form, the pH value of the base mass for producing said administration form is approximated or adapted to the physiological pH value of the mucosa to which the administration form is to be applied, said pH value of the mucosa being: at 8 to 9 when said mucosa is a herbivoral mucosa, between 5.5 and 6.5 when said mucosa is a human oral mucosa; at about 6 when said mucosa is a human nasal mucosa; or at about 4 when said mucosa is a human vaginal mucosa, ~~and wherein said at least one active substance is selected from the group consisting of pharmaceutically active substances and aroma substances.~~

2. (cancelled)

3. (cancelled)

4. (previously presented) The administration form according to claim 1, wherein the polymer portion is 5 to 95%-wt. relative to the dry mass of the administration form.
5. (previously presented) The administration form according to claim 1, wherein the content of said pharmaceutically active substance is 0.1 to 50%-wt., relative to the dry mass of the administration form.
6. (previously presented) The administration form according to claim 1, wherein the content of said aroma substance is 0.1 to 20%-wt., relative to the dry mass of the administration form.
7. (cancelled)
8. (previously presented) The administration form according to claim 1, wherein the pH value is approximated or adapted by using a chemical selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, phosphoric acid and a buffer system.
9. (previously presented) The administration form according to claim 1, wherein said administration form is mucoadhesive.
10. (previously presented) The administration form according to claim 1, wherein said administration form is disintegratable.
11. (previously presented) The administration form according to claim 10, wherein said administration form disintegrates within 15 minutes after having been introduced in an aqueous medium.
12. (cancelled)
13. (previously presented) The administration form according to claim 1, wherein said administration form contains at least one adjuvant selected from the group consisting of

filling agents, colourants, flavourings, aroma substances, fragrant substances, emulsifiers, plasticizers, sweeteners, preservatives, permeation-enhancing substances, and antioxidants.

14. (previously presented) The administration form according to claim 13, wherein the portion of said at least one adjuvant amounts to up to 30%-wt. relative to the dry mass of the administration form.

15. (withdrawn) A method for transmucosal administration of active substances, comprising the step of applying an administration form according to claim 1 to a mucosa of a person or of an animal.

16. (withdrawn) A process for the production of a film-shaped administration form for transmucosal administration of at least one active substance, comprising the steps of:

preparing a base mass comprising a solvent or a mixture of solvents, at least one matrix-forming polymer and at least one active substance;

approximating or adapting the pH value of the base mass to the physiological pH value of the mucous membrane to which the administration form is to be applied;

extruding the base mass to form a moist film;

drying the moist film; and

singularizing the administration form; wherein

said at least one active substance is selected from the group consisting of pharmaceutically active substances and aroma substances.

17. (withdrawn) The process according to claim 16, comprising the step of using water as the solvent or as at least one of the solvents of the mixture of solvents.

18. (withdrawn) The process according to claim 16, wherein the step of approximating or adapting the pH value of the base mass comprises the step of adjusting the pH value of the base mass to a value in the range between 5 and 9.

19. (withdrawn) The process according to claim 18, wherein the step of adjusting the the pH value is accomplished by adding a chemical selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, phosphoric acid and a buffer system.

20. (cancelled)

21. (previously presented) The administration form according to claim 4, wherein the polymer portion is 15 to 75%-wt. relative to the dry mass of the administration form.

22. (previously presented) The administration form according to claim 5, wherein the content of said pharmaceutically active substance is 0.5 to 20%-wt. relative to the dry mass of the administration form.

23. (previously presented) The administration form according to claim 6, wherein the content of said aroma substance is 1 to 10%-wt. relative to the dry mass of the administration form.

24. (previously presented) The administration form according to claim 1, wherein the pH value of the base mass was adjusted to a value in the range between 6 and 8.5.

25. (previously presented) The administration form according to claim 24, wherein the pH value of the base mass was adjusted to a value in the range between 6.5 and 8.

26. (previously presented) The administration form according to claim 8, wherein said buffer system is a phosphate buffer.

27. (previously presented) The administration form according to claim 11, wherein said administration form disintegrates within 3 minutes after having been introduced in an aqueous medium.

28. (previously presented) The administration form according to claim 27, wherein said administration form disintegrates within 60 seconds after having been introduced in an aqueous medium.

29. (previously presented) The administration form according to claim 13, wherein the portion of said at least one adjuvant amounts to up to 1 to 20%-wt. relative to the dry mass of the administration form.

30. (withdrawn) The process according to claim 18, comprising the step of adjusting the pH value of the base mass to a value in the range between 6 and 8.5.

31. (withdrawn) The process according to claim 30, comprising the step of adjusting the pH value of the base mass to a value in the range between 6.5 and 8.

32. (withdrawn) The process according to claim 19, wherein said buffer system is a phosphate buffer.

33. (canceled)

34. (previously presented) The administration form according to claim 33, wherein said salts comprise hydrochlorides, citrates and salicylates.

35. (previously presented) The administration form according to claim 1, wherein said at least one active substance comprises one or more aroma substances, without a pharmaceutical active substance being included in the administration form.

36. (withdrawn) The method according to claim 15, wherein said mucosa is selected from the group consisting of oral mucosa, gingival mucosa, vaginal mucosa, nasal mucosa and rectal mucosa.

37. (new) A film-shaped administration form for transmucosal administration of at least one active substance, said administration form being applied to the oral mucosa of a herbivore, to the human oral mucosa, to the human nasal mucosa or to the human vaginal mucosa in a manner avoiding mucosal irritation, said administration form comprising:

a base mass for producing said administration form, said base mass comprising at least one matrix-forming polymer and at least one pharmaceutical active substance which is present in salt form, wherein said at least one matrix-forming polymer is selected from the group consisting of pullulan, polyacrylamides, chitosan, arabinogalactan, galactomannan, agar-agar, agarose and carrageenan, said base mass having a pH value in the presence of water or of a water-containing solvent mixture, wherein said administration form is a dried film, and wherein, during the production of said administration form, the pH value of the base mass for producing said administration form is approximated or adapted to the physiological pH value of the mucosa to which the administration form is to be applied, or at about 4 when said mucosa is a human vaginal mucosa.

38. (new) A film-shaped administration form for transmucosal administration of at least one active substance, said administration form being applied to the oral mucosa of a herbivore, to the human oral mucosa, to the human nasal mucosa or to the human vaginal mucosa in a manner avoiding mucosal irritation, said administration form comprising:

a base mass for producing said administration form, said base mass comprising at least one matrix-forming polymer and at least one pharmaceutical active substance which is present in salt form, wherein said at least one matrix-forming polymer is selected from the group consisting of pullulan, polyacrylamides, chitosan, arabinogalactan, galactomannan, agar-agar, agarose and carrageenan, said base mass having a pH value in the presence of water or of a water-containing solvent mixture, wherein said administration form is a dried film, and wherein, during the production of said administration form, the pH value of the base mass for producing said administration form is approximated or adapted to the physiological pH value of the mucosa to which the administration form is to be applied, said pH value of the mucosa being: at 8 to 9 when said mucosa is a herbivoral mucosa, between 5.5 and 6.5 when said mucosa is a human oral mucosa; at about 6 when said mucosa is a human nasal mucosa; or at about 4 when said mucosa is a human vaginal mucosa.

39. (new) The multilayered administration form according to claim 1, wherein the individual layers of the multilayered administration form differ from one another with respect to at least one parameter selected from the group of parameters consisting of active substance content, active substance concentration and content additives.